Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) – Pipeline Review, H2 2016’, provides in depth analysis on Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1)

The report reviews Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Amgen Inc.

Antisense Therapeutics Limited

Astellas Pharma Inc.

AstraZeneca Plc

Axelar AB

Boehringer Ingelheim GmbH

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

Genmab A/S

Immunomedics, Inc.

Insmed Incorporated

Merck & Co., Inc.

Merrimack Pharmaceuticals, Inc.

Novartis AG

PharmAbcine, Inc.

Prometheon Pharma, LLC

ProteoThera, Inc.

Silver Creek Pharmaceuticals, Inc.

Sucampo Pharmaceuticals, Inc.

TyrNovo Ltd.

XL-protein GmbH

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC

2.7.10.1) Overview 10

Therapeutics Development 11

Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC

2.7.10.1) - Products under Development by Stage of Development 11

Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC

2.7.10.1) - Products under Development by Therapy Area 12

Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC

2.7.10.1) - Products under Development by Indication 13

Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC

2.7.10.1) - Pipeline Products Glance 15

Late Stage Products 15

Early Stage Products 16

Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC

2.7.10.1) - Products under Development by Companies 17

Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC

2.7.10.1) - Products under Development by Universities/Institutes 21

Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC

2.7.10.1) - Therapeutics Assessment 23

Assessment by Monotherapy/Combination Products 23

Assessment by Mechanism of Action 24

Assessment by Route of Administration 26

Assessment by Molecule Type 28

Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC

2.7.10.1) - Companies Involved in Therapeutics Development 30

Amgen Inc. 30

Antisense Therapeutics Limited 31

Astellas Pharma Inc. 32

AstraZeneca Plc 33

Axelar AB 34

Boehringer Ingelheim GmbH 35

Eli Lilly and Company 36

F. Hoffmann-La Roche Ltd. 37

Genmab A/S 38

Immunomedics, Inc. 39

Insmed Incorporated 40

Merck & Co., Inc. 41

Merrimack Pharmaceuticals, Inc. 42

Novartis AG 43

PharmAbcine, Inc. 44

Prometheon Pharma, LLC 45

ProteoThera, Inc. 46

Silver Creek Pharmaceuticals, Inc. 47

Sucampo Pharmaceuticals, Inc. 48

TyrNovo Ltd. 49

XL-protein GmbH 50

Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC

2.7.10.1) - Drug Profiles 51

1R-15-15 - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

1R-2b - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

1R-3s - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

1R-E1-E1 - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

ATL-1101 - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

AXL-1717 - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

AZD-3463 - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

BI-893923 - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

CT-707 - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

dalotuzumab - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

Drugs to Antagonize IGF-1 Receptor for Acute Lung Injury and Pulmonary Fibrosis - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

ganitumab - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

Hex-hR1 - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

istiratumab - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

lenaldekar - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

linsitinib - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

M-590 - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

mecasermin rinfabate - Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

Monoclonal Antibody to Antagonize IGF-IR and Inhibit VEGF for Oncology - Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

Monoclonal Antibody to Antagonize IGFR-1 for Oncology and Inflammatory Disorders - Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

NT-157 - Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

NT-219 - Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

Protein to Activate Insulin Like Growth Factor 1 Receptor for Migraine - Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

Protein to Agonize Insulin Like Growth Factor 1 Receptor for Hormone Replacement Therapy - Drug Profile 83

Product Description 83

Mechanism Of Action 83

R&D Progress 83

Recombinant Insulin Like Growth Factor 1 - Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

Recombinant Protein to Agonize IGF-1 Receptor for Osteoarthritis - Drug Profile 85

Product Description 85

Mechanism Of Action 85

R&D Progress 85

Recombinant Protein to Antagonize IGF-1R for Oncology - Drug Profile 86

Product Description 86

Mechanism Of Action 86

R&D Progress 86

Recombinant Proteins to Agonize IGF-1R for Myocardial Infarction - Drug Profile 87

Product Description 87

Mechanism Of Action 87

R&D Progress 87

RU-105 - Drug Profile 88

Product Description 88

Mechanism Of Action 88

R&D Progress 88

Small Molecule to Antagonize IGF-1R for Oncology - Drug Profile 89

Product Description 89

Mechanism Of Action 89

R&D Progress 89

Small Molecules to Antagonize IGF-1R for Oncology - Drug Profile 90

Product Description 90

Mechanism Of Action 90

R&D Progress 90

Small Molecules to Inhibit IGF-1R/IR for Oncology - Drug Profile 91

Product Description 91

Mechanism Of Action 91

R&D Progress 91

Small Molecules to Inhibit IGF1R for Breast Cancer - Drug Profile 92

Product Description 92

Mechanism Of Action 92

R&D Progress 92

teprotumumab - Drug Profile 93

Product Description 93

Mechanism Of Action 93

R&D Progress 93

Vaccine to Target HER-2, IGFBP-2 and IGF1R for Breast Cancer - Drug Profile 95

Product Description 95

Mechanism Of Action 95

R&D Progress 95

vesiculin - Drug Profile 96

Product Description 96

Mechanism Of Action 96

R&D Progress 96

XGFR-2 - Drug Profile 97

Product Description 97

Mechanism Of Action 97

R&D Progress 97

XGFR-4 - Drug Profile 98

Product Description 98

Mechanism Of Action 98

R&D Progress 98

XL-110 - Drug Profile 99

Product Description 99

Mechanism Of Action 99

R&D Progress 99

Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC

2.7.10.1) - Dormant Projects 100

Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC

2.7.10.1) - Discontinued Products 107

Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC

2.7.10.1) - Featured News & Press Releases 111

Jun 30, 2016: Shire Announces Top-Line Results for Phase 2 Trial of SHP607 in Extremely Premature Infants 111

Mar 16, 2016: Merrimack to Present on MM-141 (istiratumab) at the 2016 American Association for Cancer Research Annual Meeting 112

Jul 29, 2015: CMC Biologics and River Vision Development Corporation Announce Manufacturing Agreement for RV001, a Monoclonal Antibody to Treat Grave’s Orbitopathy 112

May 05, 2015: Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in Biomarker-Selected Patients with Metastatic Pancreatic Cancer 113

Apr 21, 2015: First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 113

Mar 17, 2015: Study suggests precision medicine for adrenal cancer 115

Jan 20, 2015: Merrimack Pharmaceuticals Presents First-in-human study of MM-141 at the American Society of Clinical Oncology 2015 Gastrointestinal Cancers Symposium 116

Nov 05, 2014: FDA Grants Orphan Drug Designation to Merrimack Pharmaceuticals MM-141 for the Treatment of Pancreatic Cancer 117

Jun 02, 2014: Merrimack Pharmaceuticals Presents Phase 1 Clinical Data From MM-141 at the 2014 ASCO Annual Meeting 117

Feb 18, 2014: Preclinical Study Results of Merrimack's MM-141 Published in Molecular Cancer Therapeutics 118

Jan 14, 2014: AmorChem Invests In A Potential Therapy For Late-Stage Breast Cancer 119

Dec 27, 2013: Axelar announces final data from Phase II study with AXL1717 in lung cancer 120

Oct 15, 2013: Merrimack Pharmaceuticals to Present Preclinical Data On MM-141 at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 120

Jun 11, 2013: Genmab To Restart Clinical Development Of Teprotumumab In Phase II Study For Treatment Of Active Thyroid Eye Disease 121

Jun 11, 2013: River Vision Receives US Orphan Drug Designation For RV001 For Treatment Of Graves Orbitopathy 121

Appendix 122

Methodology 122

Coverage 122

Secondary Research 122

Primary Research 122

Expert Panel Validation 122

Contact Us 122

Disclaimer 123

List of Tables

List of Tables

Number of Products under Development for, H2 2016 11

Number of Products under Development by Therapy Area, H2 2016 12

Number of Products under Development by Indication, H2 2016 13

Comparative Analysis by Late Stage Development, H2 2016 15

Comparative Analysis by Early Stage Products, H2 2016 16

Number of Products under Development by Companies, H2 2016 17

Products under Development by Companies, H2 2016 18

Products under Development by Companies, H2 2016 (Contd..1) 19

Products under Development by Companies, H2 2016 (Contd..2) 20

Number of Products under Investigation by Universities/Institutes, H2 2016 21

Products under Investigation by Universities/Institutes, H2 2016 22

Assessment by Monotherapy/Combination Products, H2 2016 23

Number of Products by Stage and Mechanism of Action, H2 2016 25

Number of Products by Stage and Route of Administration, H2 2016 27

Number of Products by Stage and Molecule Type, H2 2016 29

Pipeline by Amgen Inc., H2 2016 30

Pipeline by Antisense Therapeutics Limited, H2 2016 31

Pipeline by Astellas Pharma Inc., H2 2016 32

Pipeline by AstraZeneca Plc, H2 2016 33

Pipeline by Axelar AB, H2 2016 34

Pipeline by Boehringer Ingelheim GmbH, H2 2016 35

Pipeline by Eli Lilly and Company, H2 2016 36

Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 37

Pipeline by Genmab A/S, H2 2016 38

Pipeline by Immunomedics, Inc., H2 2016 39

Pipeline by Insmed Incorporated, H2 2016 40

Pipeline by Merck & Co., Inc., H2 2016 41

Pipeline by Merrimack Pharmaceuticals, Inc., H2 2016 42

Pipeline by Novartis AG, H2 2016 43

Pipeline by PharmAbcine, Inc., H2 2016 44

Pipeline by Prometheon Pharma, LLC, H2 2016 45

Pipeline by ProteoThera, Inc., H2 2016 46

Pipeline by Silver Creek Pharmaceuticals, Inc., H2 2016 47

Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016 48

Pipeline by TyrNovo Ltd., H2 2016 49

Pipeline by XL-protein GmbH, H2 2016 50

Dormant Projects, H2 2016 100

Dormant Projects (Contd..1), H2 2016 101

Dormant Projects (Contd..2), H2 2016 102

Dormant Projects (Contd..3), H2 2016 103

Dormant Projects (Contd..4), H2 2016 104

Dormant Projects (Contd..5), H2 2016 105

Dormant Projects (Contd..6), H2 2016 106

Discontinued Products, H2 2016 107

Discontinued Products (Contd..1), H2 2016 108

Discontinued Products (Contd..2), H2 2016 109

Discontinued Products (Contd..3), H2 2016 110

List of Figures

List of Figures

Number of Products under Development for, H2 2016 11

Number of Products under Development by Therapy Area, H2 2016 12

Number of Products under Development by Top 10 Indication, H2 2016 13

Comparative Analysis by Early Stage Products, H2 2016 16

Assessment by Monotherapy/Combination Products, H2 2016 23

Number of Products by Mechanism of Actions, H2 2016 24

Number of Products by Stage and Mechanism of Actions, H2 2016 24

Number of Products by Routes of Administration, H2 2016 26

Number of Products by Stage and Routes of Administration, H2 2016 26

Number of Products by Molecule Types, H2 2016 28

Number of Products by Stage and Molecule Type, H2 2016 28

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports

Analytics by GoSquared